EU Marketing Authorisation of Orphan Medicinal Products and Its Impact on Related Research

Authors

Sara Gerke, General Manager, Institute for German, European and International Medical Law, Public Health Law and Bioethics, Universities of Heidelberg and MannheimGermany
Shaun Pattinson, Durham University

Author ORCID iD

https://orcid.org/0000-0002-5718-3982

Document Type

Article

Publication Date

11-10-2017

Abstract

Over the last 15 years, there has been a steady increase in the development of orphan medicinal products (omps). This raises an important question: What impact does the eu marketing authorisation of an omp have on related research? This article establishes that the key orphan incentive, namely the 10‑year market exclusivity provision laid down in Article 8 of the eu Regulation on omps (Regulation 141/2000), has a huge potential impact on related research. It is argued that this provision can make it too difficult for researchers/sponsors to attain marketing approval for closely related products. This article advances two proposals to address this problem. First, it argues for new principles for assessing similarity, so as to clarify and narrow the ambit of market exclusivity. Secondly, it argues for improved conditions for a demonstration of ‘clinical superiority’ for similar omps.

Publication Title

European Journal of Health Law

Recommended Citation

Sara Gerke and Shaun Pattinson, EU Marketing Authorisation of Orphan Medicinal Products and Its Impact on Related Research, 24 European Journal of Health Law 541 (2017).